Literature DB >> 9593263

Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia.

T M Schenk1, A Keyhani, S Bottcher, K O Kliche, A Goodacre, J Q Guo, R B Arlinghaus, H M Kantarjian, M Andreeff.   

Abstract

Acute lymphocytic leukemia (ALL) is considered a clonal disease restricted to the lymphoid compartment. The Philadelphia chromosome (Ph) is found in a subset of ALL with poor prognosis. Here we present the largest series of Ph+ ALL analyzed for involvement of the myeloid compartment. For the first time at a single cell level the presence of Ph in lineages other than lymphoid is demonstrated. Granulocytes from nine patients diagnosed with BCR-ABL + ALL (eight Ph+, one Ph-) were purified using two layer density gradient separation. They were further identified by the morphology of DAPI-stained nuclei and studied for the presence of the Ph by fluorescence in situ hybridization (FISH) using a BCR-ABL dual-color probe. Ph was demonstrated in 30 to 93% of granulocytes in all patients. FISH identified major and minor BCR gene breakpoints (M-bcr and m-bcr). In one patient, with CD19+/34+/33-/2-/3-/7-/10- lymphoblasts, involvement of B cells (CD19+), T cells (CD3+), myeloid (CD13+), erythroid (glycophorin A+) cells was found by FISH following fluorescence-activated cell sorting (FACS). The diagnosis of ALL as opposed to lymphoblastic transformation of CML was established based on clinical and laboratory data including Western blot results demonstrating the presence of p190/m-bcr in five of the nine cases studied. Results suggest that Ph+ ALL originates from a pluripotent stem cell.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593263     DOI: 10.1038/sj.leu.2400986

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Deborah A Thomas; Susan O'Brien; Rebecca Garris; Stefan Faderl; Xuelin Huang; Sijin Wen; Jan A Burger; Alessandra Ferrajoli; Partow Kebriaei; Richard E Champlin; Zeev Estrov; Pramoda Challagundla; Sa A Wang; Rajyalakshmi Luthra; Jorge E Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

2.  Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy.

Authors:  Xavier Thomas
Journal:  World J Stem Cells       Date:  2012-06-26       Impact factor: 5.326

3.  Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.

Authors:  James Scott McClellan; Christopher Dove; Andrew J Gentles; Christine E Ryan; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

4.  Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.

Authors:  Jonathan A Webster; Leo Luznik; Hua-Ling Tsai; Philip H Imus; Amy E DeZern; Keith W Pratz; Mark J Levis; Ivana Gojo; Margaret M Showel; Gabrielle Prince; Javier Bolaños-Meade; Lukasz P Gondek; Gabriel Ghiaur; W Brian Dalton; Tania Jain; Ephraim J Fuchs; Douglas E Gladstone; Christian B Gocke; Syed Abbas Ali; Carol Ann Huff; Ivan M Borrello; Lode Swinnen; Nina Wagner-Johnston; Richard F Ambinder; Richard J Jones; B Douglas Smith
Journal:  Blood Adv       Date:  2020-10-27

Review 5.  Leukemia stem cells and human acute lymphoblastic leukemia.

Authors:  Kathrin M Bernt; Scott A Armstrong
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

6.  Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.

Authors:  Nicholas J Short; Hagop M Kantarjian; Elias J Jabbour; Susan M O'Brien; Stefan Faderl; Jan A Burger; Rebecca Garris; Wei Qiao; Xuelin Huang; Nitin Jain; Marina Konopleva; Tapan M Kadia; Naval Daver; Gautam Borthakur; Jorge E Cortes; Farhad Ravandi
Journal:  Am J Hematol       Date:  2016-02-09       Impact factor: 10.047

7.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.